Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Exclusion criteria

• ✕. Liver function test suggest AST or ALT levels \>3× upper limit of normal (ULN);
• ✕. Total serum bilirubin value \>2.5×ULN;if combined with Gilbert syndrome, total bilirubin \>3×ULN and direct bilirubin value \>2.5×ULN;
• ✕. History of bridging fibrosis, cirrhosis;
• ✕. Left ventricular ejection fraction \<45%;
• ✕. New York Heart Association (NYHA) class III or IV congestive heart failure;
• ✕. Severe arrhythmia requiring medical treatment;
• ✕. Uncontrolled hypertension or unstable angina pectoris;
• ✕. Myocardial infarction or bypass or stent surgery within 12 months before drug administration;